- Home
- ENGN vs DCTH Comparison
ENGN vs DCTH Comparison
Compare ENGN & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- DCTH
- Stock Information
- Founded
- ENGN 1999
- DCTH 1988
- Country
- ENGN Canada
- DCTH United States
- Employees
- ENGN N/A
- DCTH N/A
- Industry
- ENGN
- DCTH Medical/Dental Instruments
- Sector
- ENGN
- DCTH Health Care
- Exchange
- ENGN Nasdaq
- DCTH Nasdaq
- Market Cap
- ENGN 321.5M
- DCTH 388.3M
- IPO Year
- ENGN N/A
- DCTH N/A
- Fundamental
- Price
- ENGN $6.07
- DCTH $11.02
- Analyst Decision
- ENGN Buy
- DCTH Strong Buy
- Analyst Count
- ENGN 8
- DCTH 4
- Target Price
- ENGN $21.50
- DCTH $24.50
- AVG Volume (30 Days)
- ENGN 222.4K
- DCTH 505.0K
- Earning Date
- ENGN 09-11-2025
- DCTH 11-07-2025
- Dividend Yield
- ENGN N/A
- DCTH N/A
- EPS Growth
- ENGN N/A
- DCTH N/A
- EPS
- ENGN N/A
- DCTH 0.06
- Revenue
- ENGN N/A
- DCTH $70,240,000.00
- Revenue This Year
- ENGN N/A
- DCTH $159.22
- Revenue Next Year
- ENGN N/A
- DCTH $42.78
- P/E Ratio
- ENGN N/A
- DCTH $197.14
- Revenue Growth
- ENGN N/A
- DCTH 491.35
- 52 Week Low
- ENGN $2.65
- DCTH $8.08
- 52 Week High
- ENGN $11.00
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- ENGN 56.13
- DCTH 51.47
- Support Level
- ENGN N/A
- DCTH N/A
- Resistance Level
- ENGN $6.54
- DCTH $11.38
- Average True Range (ATR)
- ENGN 0.50
- DCTH 0.43
- MACD
- ENGN -0.12
- DCTH -0.38
- Stochastic Oscillator
- ENGN 92.74
- DCTH 92.37
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.